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Short Peptides as Inhibitors of Amyloid Aggregation 
Bradley Neddenriep, Anastasia Calciano, Daniel Conti, Erin Sauve, Marissa Paterson,  
Edward Bruno and David A. Moffet* 
Department of Chemistry and Biochemistry Loyola Marymount University 1 LMU Drive Los Angeles, CA 90045, USA 
Abstract: The misfolding and aggregation of proteins into amyloid has been linked to a variety of age-related diseases. 
Aggregation of proteins, such as A  in Alzheimer’s disease and Islet Amyloid Polypeptide (IAPP, amylin) in type 2 dia-
betes, appears to lead to the formation of toxic assemblies. These assemblies range in size from small oligomers (2-8 pro-
teins) to large fibrils (thousands of proteins). It remains unclear how these amyloidogenic proteins misfold and form toxic 
species, but growing evidence suggests that inhibiting the aggregation of these proteins could slow, if not prevent alto-
gether, the progression of these diseases. We describe the use of small peptides (<43 amino acids) as inhibitors of amy-
loid-based aggregation. These peptides, often short complementary segments of the amyloid proteins, can be useful (i) for 
identifying the aggregation-prone regions of the amyloid proteins (ii) as models for drug discovery and (iii) as potential 
therapeutic agents themselves.  
Keywords: Amyloid Inhibition, Peptide Libraries, ABeta, Amylin, IAPP.
INTRODUCTION 
 Many proteins are known to adopt unwanted, misfolded 
structures that can be linked to a variety of age-related dis-
eases [1-3]. Proteins such as Islet Amyloid Polypeptide 
(IAPP, amylin) in type 2 diabetes and A 42 in Alzheimer’s 
disease are known to misfold and aggregate into toxic oli-
gomers and fibers. In these amyloid diseases, proteins mis-
fold and self-assemble into a variety of structures. It remains 
unknown if these misfolded proteins are the cause of their 
respective diseases or a side-effect. However, evidence is 
accumulating to suggest that the aggregation of amyloid pro-
teins plays an important role in the development and pro-
gression of these diseases. 
 The amyloid diseases represent a serious threat to our 
overall global health. Within the United States, the economic 
and social costs associated with Alzheimer’s disease and 
type 2 diabetes have been well documented over the past 
decade. The Alzheimer’s Association estimates that 5.1 mil-
lion Americans are currently afflicted with Alzheimer’s dis-
ease [4]. Likewise, the American Diabetes Association esti-
mates that 23.6 million children and adults in the United 
States have diabetes [5]. Because the prevalence of these 
diseases increases with age, the number of people afflicted 
with Alzheimer’s disease and type 2 diabetes will increase as 
the population ages. If no treatments are found to slow these 
diseases, it is estimated that 11 to 16 million Americans will 
be afflicted with Alzheimer’s disease by 2050 [4] and as 
many as 100 million Americans could have diabetes by that 
time [6]. The economic costs of just these two amyloi-
dogenic diseases is estimated to be more than $148 billion 
annually for Alzheimer’s disease and $174 billion for type 2 
diabetes.  
*Address correspondence to this author at the Department of Chemistry and 
Biochemistry Loyola Marymount University 1 LMU Drive Los Angeles, 
CA 90045, USA; Tel: 310-338-4400; Fax: 001-310-338-2905;  
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 While the amyloidogenic proteins differ in many ways 
(length, organismal localization, amino acid compositions), 
they all form well-ordered fibrils and appear to be toxic to 
living cells [7-14]. These similarities are not solely shared by 
naturally occurring proteins, but have been identified in de-
signed proteins expressed in mammalian cells [15]. These 
results indicate that the formation of protein aggregates, 
whether they are small oligomers or large fibrils, plays a 
central role in cell toxicity and disease pathology. These 
studies suggest that the mechanism of this cellular toxicity is 
likely conserved from one amyloid protein to the next. These 
results raise the hope that if a strategy is uncovered to pre-
vent amyloid formation for one disease, the same strategy 
may lead to therapies for many, if not all, of the remaining 
amyloid diseases.  
 Many strategies are currently being assessed for prevent-
ing the formation of amyloid and toxic oligomers. Some 
strategies rely on preventing the production of the amyloid 
protein in the first place (for instance, inhibiting -secretase 
activity in A  production). Some strategies rely on removing 
the amyloid protein after it has been produced (such as using 
antibodies to remove A ). Both of these strategies hold great 
potential for slowing and/or preventing the onset of amyloid-
based diseases. However, it remains to be determined if the 
amyloid proteins themselves serve a useful purpose to the 
organism. There may be a benefit to having the protein that 
has not yet been determined. With this in mind, there have 
been some recent successes made in slowing the rate of ag-
gregation of amyloid proteins without having to remove the 
protein entirely. Several classes of small molecules have 
been identified as showing some activity toward inhibiting 
the formation of amyloid. [16-27]. While small-molecule 
aggregation inhibitors have been reported, none have been 
developed into a clinically useful therapeutic. 
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 Since 2002, we have seen a considerable increase in the 
number of reports identifying short peptides as inhibitors of 
amyloid formation. While none of these peptides have been 
developed into a therapeutic, the potential does exist. Unlike 
small-molecule inhibitors of amyloid aggregation, short pep-
tides can yield information regarding the amyloid aggregates 
themselves. Many of the peptide inhibitors are truncated 
versions of the full-length amyloid proteins. By identifying 
the sequence regions that inhibit aggregation, we can infer 
that those are the regions responsible for driving amyloid 
aggregation. In this review, we will focus on the short pep-
tide sequences comprised of naturally occurring amino acids 
that have been identified for their ability to inhibit the aggre-
gation of the amyloidogenic proteins A  (Alzheimer’s dis-
ease) and IAPP (type 2 diabetes).  
PEPTIDE INHIBITION OF ABETA AGGREGATION 
 Peptides showing an ability to inhibit the aggregation of 
A  can be organized into two major groups; rationally de-
signed peptides (which are typically similar in sequence to 
that of wild-type A ) and randomly generated peptides 
(those which are identified from peptide libraries that may, 
or may not, show sequence similarity to wild-type A ). The 
advances made in molecular biology and biotechnology in 
the past decade have made it possible to construct and screen 
large peptide libraries to identify those sequences that inter-
act with A . These library-screening experiments, which 
were either impossible or impractical just a few years ago, 
have successfully identified several amyloid inhibitors.  
Rationally Designed Peptide Inhibitors of A   
Aggregation 
 The earliest attempts to identify A  aggregation inhibi-
tors came from the sequence of A  itself (Table 1). Many of 
the first peptide inhibitors were designed to target the aggre-
gation-prone hydrophobic core region of A . This region 
(LVFFA) is considered by many to be the primary aggrega-
tion-prone site of A  and is often termed the self-recognition 
site [28-30]. Many rationally designed peptides retain the 
LVFFA sequence, with the hope that the inhibitor peptide 
will selectively bind to the analogous sequence of natural 
A 42 [28, 31-34]. What often differs among these peptides 
are the N and C –terminal amino acids surrounding the 
LVFFA core. These surrounding residues are thought to act 
as aggregation blockers (termed -sheet breakers), prevent-
ing additional amyloid peptides from adhering to the A -
peptide complex [35]. Many of these LVFFA peptides, and 
their later-generation variants, have been shown to inhibit 
A  aggregation at stoichiometric concentrations and rescue 
living cells from the toxic effects of A 42. For example, 
Garno and coworkers recently synthesized and studied 15 
different variants having KLVFF as the core sequence (addi-
tional residues were added to the N-terminus and/or the C-
terminus of this core sequence) [31]. From Thioflavin T and 
transmission electron microscopy experiments, nearly all of 
these peptides possessed some ability to inhibit aggregation 
at a 1:1 molar ratio (40 μM peptide to 40 μM A 40). Several 
peptides inhibited aggregation by approximately 80% com-
pared to samples lacking the inhibitory peptides. Atomic 
force microscopy was used to identify the aggregation prod-
ucts of A 40 alone, the peptides alone and A 40 in the pres-
ence of the peptide inhibitors. Several peptides were found to 
self-aggregate into spherical assemblies, yet still showed 
inhibitory capacity. They found that placing positively 
charged residues at the N-terminal end of the KLVFF se-
quence were less likely to inhibit than if positive amino acids 
were placed at the C-terminal end. The authors also con-
cluded that the peptides with the highest affinity to A 40 
showed the greatest ability to inhibit amyloid-based aggrega-
tion. These results seem to be typical of the KLVFF core 
peptide inhibitors. These peptides demonstrate the potential 
of rationally designed peptide inhibitors as amyloid blocking 
agents. 
Table 1. Peptide Inhibitors of A 42 
 
Table 2. Peptide Inhibitors of IAPP 
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 The hydrophobic core of A 42 is not the only region 
targeted for inhibition of aggregation. A 42 aggregation has 
been inhibited using C-terminal fragment (CTF) sequences 
of various lengths [36-38]. The best of these inhibitors 
spanned the final 13, 11 and 4 amino acids of A 42 [38], 
indicating that the length of the inhibitor peptide did not nec-
essarily correlate with inhibitory propensity. Instead, the best 
correlation between CTF and their physical properties ap-
peared to rely on the ability of the CTF to form a coil-turn 
conformation [38]. This conformation seems to appear in 
other inhibitory models, such as the peptide hairpin inhibitor 
of Teplow and coworkers [39]. While this peptide does con-
tain one D-amino acid (D-Proline), the polypeptide is be-
lieved to form a hairpin turn held together by a disulfide 
bridge. 
 The rationally designed peptides have proven to be a 
strong class of inhibitory agents for A 42. These peptides 
continue to be modified with the ultimate goal to increase 
their ability to inhibit amyloid aggregation. Many of these 
peptides have been found to protect living cells from toxic 
amyloid aggregates. Perhaps future iterations of these pep-
tides will show even greater ability to protect cellular viabil-
ity. 
Peptide Inhibitors of A  Aggregation Selected from 
Combinatorial Libraries  
 Advances in molecular biology, coupled with the de-
creased cost of DNA synthesis, have led to a greater ability 
to generate high-quality gene/protein libraries [40]. Libraries 
that once took months to construct, can now be done in a 
matter of weeks. While the ability to construct gene libraries 
has greatly evolved over the past decade, the ability to select 
for those variants that show a desirable activity has not. 
There are very few techniques in the literature that describe 
screens to select for peptides that inhibit amyloid aggrega-
tion and protect living cells from toxic protein aggregates. 
Despite this paucity of screening techniques, those screens 
that have been utilized have proven to be successful at iden-
tifying multiple amyloid-inhibiting peptides. We will discuss 
each of these screening techniques and the inhibitory pep-
tides they have identified. 
Peptides Identified Using Phage-Display 
 Phage display has proven to be an excellent method for 
screening large libraries of peptides to select for those that 
bind to an epitope of interest [41]. Many of the libraries 
screened by phage display have targeted large pep-
tides/proteins. These libraries of larger peptides have gener-
ated sequences that inhibit A  aggregation, but may prove 
difficult to convert into a therapeutically useful drug. For 
example, several papers have been published recently that 
describe antibody-based, affibody, and other scaffold-based 
proteins selected by phage display [42-52]. Many of these 
selected proteins have been shown to inhibit aggregation, but 
their therapeutic potential remains untested. 
 Kamijo and coworkers recently screened a randomized 
heptapeptide library against A 42 [53]. Their goal was to 
identify peptides that could bind A 42, but did not necessar-
ily possess sequence similarities to A 42. They identified 
several peptides, rich in arginines, that showed in vitro abil-
ity to inhibit A 42 aggregation. Size-exclusion chromatog-
raphy and SDS-PAGE gel-shift assays indicated that several 
of these selected peptides kept A 42 from forming soluble 
oligomers [53]. Additional experiments will need to be per-
formed to assess how these peptides inhibit aggregation. Of 
specific interest is why arginine-rich sequences were highly 
selected in this screen. 
 Not all peptides identified with phage display have been 
found to inhibit aggregation. Kiessling and coworkers identi-
fied several peptides that could bind to different aggregation 
states of A 40 [54]. While several peptides were identified 
that could bind to A 40, none slowed the rate of aggregation, 
and many increased aggregation. Therapeutically, this in-
crease in aggregation could be beneficial if, in fact, aggre-
 
Fig. (1). (A) Amyloidogenic peptides, such as A 42 and IAPP self-assemble, ultimately leading to the formation of amyloid. (B) When 
linked to an amyloid peptide, EGFP does not fold or fluoresce. The aggregation of the amyloid peptides prevents proper folding and fluores-
cence of EGFP. (C) Inhibitors that prevent the self-assembly of the amyloid peptides allow the EGFP to fold and fluoresce. 
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gated A  is less toxic than small oligomers. These aggrega-
tion-enhancing peptides may function to help sequester 
A 40 into less toxic fibrils rather than the more toxic soluble 
oligomers. 
Peptides Identified Using A 42-EGFP  
 Hecht and coworkers described the use of a GFP-based 
screen to assess the in vivo aggregation propensity of A 42 
in E. coli cells [29, 55]. This screen has been used to assess 
the aggregation potential of A  mutants [55-57] as well as to 
screen for small molecules that can inhibit aggregation [58]. 
We recently used this screen, replacing GFP with enhanced 
GFP (EGFP) to select for mutants of IAPP that resisted ag-
gregation [59]. In this screen, the amyloid protein (such as 
A 42 or IAPP) is genetically fused to the reporter protein 
EGFP. When expressed in E. coli, the Amyloid-EGFP fusion 
proteins produce virtually no green color or fluorescence due 
to the propensity of the amyloid proteins to aggregate (Fig. 
1). However, when the amyloid proteins are prevented from 
aggregating (either by mutagenesis or in the presence of an 
aggregation inhibitor), the fused EGFP folds and fluoresces 
brightly.  
 We have recently used this screen to select peptides from 
different combinatorially randomized libraries for their abil-
ity to inhibit A 42 aggregation [60]. Combinatorially diverse 
library peptides were co-expressed in E. coli with the A 42-
EGFP fusion protein. Peptides that prevented the aggregation 
of the A 42 allowed EGFP to fold and fluoresce. Individual 
E. coli colonies expressing both a library peptide and amy-
loid-EGFP were screened to select for those colonies that 
showed the greatest fluoresce. Using this screen, we identi-
fied three short peptides capable of inhibiting A 42 aggrega-
tion [60]. We believe this screen can be used to select for 
increasingly potent inhibitors of A 42 by improving the se-
lection conditions and the combinatorial library design.  
 Gene libraries can be easily constructed using a variety of 
techniques. Gene libraries can be designed to encode for 
short peptides targeted to anneal to, and disrupt aggregation 
of, the amyloidogenic A 42 peptide. For example, Fig (2) 
shows two peptide libraries targeted to mimic each of the 
two hydrophobic regions of A 42. Both gene libraries were 
constructed using synthetic single-stranded oligos  (Table 3) 
and pieced together using oligo overlap and extension (Fig. 
3). Gene variability was introduced to the gene libraries by 
using degenerate codons encoding for combinatorial mix-
tures of amino acids (Table 3).  
 Both peptide libraries were designed to mimic the hydro-
phobic patches of A 42, with the intention of producing pep-
tides that could anneal to the monomeric form of A 42. Also 
designed into the peptide libraries are strongly polar and 
charged aspartic acid residues. These acidic residues are in-
tended to incorporate a strongly charged “bump” on the li-
brary peptides that prevents the aggregation of additional 
A 42 proteins to an A 42-library peptide complex. The li-
brary peptides are designed to act as two-sided patches; one 
Library 1: 5’-CTAGCTGT CAT ATG TCT AAC AAA GGC GCG ANT ANT GNT 
CTG ATG GNT GNT GNT GNT GNT ATT GCG GAT AGT CAT AGT TAA-3’, 
Library 2: 5’-CTAGCTGT CAT ATG CAG AAA CTG GNT DTN DTN GCG GAA 
GNT GNT GGC TCT AAC AAA TAA ATT GCG GAT AGT CAT AGT TAA-3’, 
Reverse sequence for both libraries: 5’- CGATAGGAC GAATTC CAG TGG TAG 
CTT GTG TGC CAA CAG TAG TTA ACG GTA GAA CCG TTA ACT ATG ACT 
ATC CGC AAT -3’. 
 
Fig. (2). Amino Acid Sequences of A 42 and Library 1 and Library 2 Peptides. The amino acid sequence for A 42 is shown. Library 1 was 
constructed to have mixtures of amino acids in the bold-faced positions. Degenerate gene construction: Codon ANT encodes for an equal 
mixture of I, T, N and S. Codon GNT encodes for an equal mixture of V, A, D and G. Codon NTN encodes for a mixture of F, L, I, M and V.  
Table 3. Oligos Used for the Construction of Gene Libraries 1 and 2 
Library 1 Forward  5’-CTAGCTGT CAT ATG TCT AAC AAA GGC GCG ANT ANT GNT CTG ATG GNT GNT GNT GNT GNT ATT GCG GAT 
AGT CAT AGT TAA-3’ 
Library 2 Forward  5’-CTAGCTGT CAT ATG CAG AAA CTG GNT DTN DTN GCG GAA GNT GNT GGC TCT AAC AAA TAA ATT GCG 
GAT AGT CAT AGT TAA-3’ 
Reverse  5’- CGATAGGAC GAATTC CAG TGG TAG CTT GTG TGC CAA CAG TAG TTA ACG GTA GAA CCG TTA ACT ATG 
ACT ATC CGC AAT -3’ 
Degenerate codons are underlined. Complementary regions are colored blue. All oligos are written from 5’-3’. N: equal mixture of A, T, G and C. D: Equal mixture of A, G and T. 
 
 Aβ42:  DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
 Library 1:                            MSNKGGIIVLMVVVVVIADSHS   
                                          TTA  AAAAA   
                                      NND  DDDDD   
                                       SSG  GGGGG 
 
 Aβ42:  DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
 Library 2:              MDKLVFFAEVVGSIADSHS  
          ALL  AA 
                           DII  DD   
                              GMM  GG 
                                 VV  
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side being sticky and annealing to monomeric A 42, and the 
other side presenting a repulsive residue (or residues) that 
prevent additional A 42 peptides from annealing. 
 The gene library is cloned into one plasmid and cotrans-
formed with the amyloid-EGFP plasmid into a suitable E. 
coli expression host (Fig. 4). The resultant colonies are trans-
ferred to plates that can induce protein expression. With this 
system, thousands of transformed colonies can be screened 
to identify those few that show elevated levels of EGFP fluo-
rescence. 
PEPTIDE INHIBITORS OF IAPP AGGREGATION 
 In type II diabetes the amyloid-forming peptide is islet 
amyloid polypeptide (IAPP, amylin). This 37 amino acid 
polypeptide misfolds and forms toxic aggregates within the 
pancreas. This misfolding into toxic aggregates, such as 
small soluble oligomers or large fibers, is believed to con-
tribute to the loss of pancreatic -cells. A great debate con-
tinues within the scientific community to identify the toxic 
form (or forms) of IAPP. While the exact role of IAPP in 
type II diabetes is unclear, it is known that IAPP is found as 
extracellular deposits of amyloid in approximately 90% of 
patients afflicted with type II diabetes [61-63]. This peptide 
is highly amyloidogenic, finding any substance to inhibit its 
aggregation could be a potent weapon in the fight against 
type 2 diabetes. 
 It is well established that rodent IAPP (rIAPP) is 
nonamyloidogenic and nontoxic. It is also established that 
rats and mice are not known to develop type II diabetes [64], 
strengthening the argument that inhibiting IAPP aggregation 
could help to prevent type 2 diabetes. Rodent IAPP, which 
differs from human IAPP by six amino acids, has been dem-
onstrated to be capable of inhibiting human IAPP aggrega-
tion [65].  
 Five of the substitutions known to convert amyloidogenic 
human IAPP into non-amyloidogenic rodent IAPP occur in 
the 20-29 region of the peptide (Table 2). Because of these 
substitutions the 20-29 region has long been described as the 
amyloidogenic region of IAPP [32, 66, 67]. Recent studies 
have indicated that several mutations outside of the 20-29 
region can hinder fibrillogenesis, and are likely important for 
aggregation [59, 68-74]. Several short peptides targeting this 
aggregation-prone region have been identified [73]. Addi-
tionally, a single mutation in the middle of this aggregation 
region, I26P, has been shown to act as a potent inhibitor of 
IAPP aggregation [70].  
 
Fig. (3). Oligo overlap and extension: Single-stranded DNA oligos were designed having complementary 3’ overhang regions (dashed lines). 
When mixed, the complementary regions anneal and act as templates for Klenow Fragment catalyzed DNA synthesis. Nucleotides not in-
volved in annealing (solid lines) can be explicitly designed base by base or combinatorially varied.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Construction and selection of peptide libraries. Cotransformed cells were plated on nitrocellulose absorbed on LB plates containing 
Ampicillin and Streptomycin. After incubation, resulting colonies are transferred to LB plates containing IPTG. Green-colored colonies are 
selected and analyzed.  
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 Insulin is an additional peptide that is known to inhibit 
IAPP aggregation [75]. Insulin is co-secreted with IAPP 
from pancreatic B-cells. While the exact role these two pep-
tides play in the development of type 2 diabetes remains to 
be determined, it is not surprising that this metabolism-
driving hormone is important in preventing IAPP aggrega-
tion. Raleigh and coworkers were able to determine the crys-
tal structure of IAPP fused to maltose binding protein [76]. 
Based on the structure of IAPP in this fusion protein, they 
were able to model the possible binding interaction between 
IAPP and the B-chain of insulin, showing the importance of 
IAPP Phe15 in this aggregation (Table 2 shows the sequence 
of insulin as well as the residues of insulin suggested as in-
teracting with IAPP).  
 In one of the few articles describing short peptide inhibi-
tors of IAPP aggregation, Fraser and coworkers tested a se-
ries of hexapeptides, each overlapping with a segment of 
IAPP [73]. When co-incubated with IAPP, several of the 
peptides, such as GAILSST appeared to decrease the density 
of fiber formation. More importantly, one peptide SNNFGA 
(Table 2) had the ability to rescue cultured cells from IAPP 
toxicity. 
OUTLOOK 
 Over the past decade, we have witnessed a great increase 
in the number of articles describing short peptides as inhibi-
tors of amyloid aggregation. Advances in molecular biology 
(which allows for the inexpensive synthesis of DNA librar-
ies) and peptide synthesis (which have lowered the costs of 
chemically synthesizing peptides) have made it possible to 
both identify and synthesize specific peptides capable of 
inhibiting aggregation. While it remains to be seen whether 
short peptides can be used as therapeutic agents in prevent-
ing the amyloid diseases, these short peptide inhibitors can 
aid in identifying the aggregation-prone regions of the amy-
loid proteins. These short peptide inhibitors can also be use-
ful in identifying the important characteristics of potential 
therapeutic agents in amyloid inhibition. Perhaps future it-
erations of peptides will be identified that can protect cells 
from amyloid aggregates as well as resist our body’s natural 
protein degradation machinery.  
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